ReviewInternational urology and nephrology2010
Cardiovascular disease in end-stage renal disease: the challenge of assessing and managing cardiac disease in dialysis patients.
Review in International urology and nephrology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04238338 (Association of Monocyte / Lymphocyte Ratio With Risk of Death and Cardiovascular Events in Peritoneal Dialysis Patients), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Association of Monocyte / Lymphocyte Ratio With Risk of Death and Cardiovascular Events in Peritoneal Dialysis Patients
Who cites it
10 citing papers in PubMed.
- Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double-blind, placebo-controlled study.Journal of nephrology · 2015Trial
- The relationship between apelin and cardiac parameters in patients on peritoneal dialysis: is there a new cardiac marker?BMC nephrology · 2014Trial
- Article
- Five-Year Change in the Renal Function After Catheter Ablation of Atrial Fibrillation.Journal of the American Heart Association · 2019Article
- Anaesthetic consideration during laparoscopic bilateral simultaneous nephrectomy.Journal of minimal access surgery · 2014Article
- Mortality risk for women on chronic hemodialysis differs by age.Canadian journal of kidney health and disease · 2014Article
- The three-year incidence of major hemorrhage among older adults initiating chronic dialysis.Canadian journal of kidney health and disease · 2014Article
- Renal anaemia treatment in haemodialysis patients in the Central and Eastern European countries in everyday clinical practice follow-up.International urology and nephrology · 2014Article
- The relationship of plasma ADMA levels with cardiac functions and metabolic parameters in peritoneal dialysis patients.Clinical and experimental nephrology · 2013Article
- Presence of glucose in dialyzing fluid and synthesis of selected lipoxygenase-derived eicosanoids during hemodialysis.International urology and nephrology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease (CVD) is the leading cause of mortality in end-stage renal disease (ESRD), approximating a 10- to 20-fold higher risk of death in dialysis patients than in the general population. Despite this, dialysis patients often undergo fewer investigations, receive less invasive procedures, and are prescribed fewer medications compared with age-matched non-ESRD patients. A lack of randomized control trials for evidence-based treatment strategies in this population may explain some of these discrepancies, but there is concern that an attitude of "therapeutic nihilism" may be impacting on the medical care of these patients. In this review, we will explore CVD in the ESRD population. Specifically, we will try to address the following issues in patients with ESRD: (1) mechanisms of CVD, (2) cardiac evaluation and the role of coronary revascularization with percutaneous or coronary artery bypass procedures, and (3) cardiac pharmacotherapy use.
Indexed as
Identifiers
20960231What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.